Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 5Triple Negative Breast Neoplasms 4Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Ovarian Neoplasms 1Neuroendocrine Tumors 1Lymphoma, Non-Hodgkin 1Lymphoma 1HER2-negative Breast Cancer 1Gastric Adenocarcinoma 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 56Carboplatin 56Bevacizumab 43Gemcitabine 20Taxes 19pembrolizumab 15Immunoglobulin G 13Disulfides 13Topotecan 12olaparib 11Cisplatin 11niraparib 9Cyclophosphamide 9liposomal doxorubicin 8Specimen Handling 7Docetaxel 6Biopsy 6mirvetuximab soravtansine 5Nivolumab 5Magnetic Resonance Spectroscopy 5Letrozole 5Hyperthermic Intraperitoneal Chemotherapy 5Drug Therapy 5Cytoreduction Surgical Procedures 5Albumin-Bound Paclitaxel 5rucaparib 4pazopanib 4oregovomab 4Surgical Procedures, Operative 4Neoadjuvant Therapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Fallopian Tube Neoplasms × taxane × Clear all
NCT03983226 2022-03-18

Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial)

Shanghai Gynecologic Oncology Group

Phase 2 Recruiting
167 enrolled
Gynecologic

Fallopian Tube Neoplasms

NCT01669226 2016-12-19

AICE

Shanghai Gynecologic Oncology Group

Phase 2 Completed
215 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡